ARTICLE
10 January 2019

Approvals For Cannabis-Related Products Face Obstacles As A Result Of The Rush By COFEPRIS

O
OLIVARES

Contributor

Our mission is to provide innovative solutions and highly specialized legal advice for clients facing the most complicated legal and business challenges in Mexico. OLIVARES is continuously at the forefront of new practice areas concerning copyright, litigation, regulatory, anti-counterfeiting, plant varieties, domain names, digital rights, and internet-related matters, and the firm has been responsible for precedent-setting decisions in patents, copyrights, and trademarks. Our firm is committed to developing the strongest group of legal professionals to manage the level of complexity and interdisciplinary orientation that clients require. During the first decade of the 21st century, the team successfully led efforts to reshape IP laws and change regulatory authorizations procedures in Mexico, not only through thought leadership and lobbying efforts, but the firm has also won several landmark and precedent-setting cases at the Mexican Federal and Supreme Courts levels, including in constitutional matters.
As mentioned in our previous newsletter, there was a clear rush by the Federal Commission against Sanitary Risks to issue guidelines to establish the criteria for the appraisal of applications of authorizations ...
Mexico Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

As mentioned in our previous newsletter, there was a clear rush by the Federal Commission against Sanitary Risks (COFEPRIS) to issue guidelines to establish the criteria for the appraisal of applications of authorizations for the commercialization, exploitation, and importation of cannabis-related products. These include products with broad industrial uses that contain cannabis and its derivative in concentrations less than 1% of tetrahydrocannabinol (THC) and to almost immediately grant some approvals. (For further reference please see our newsletter No. 63 | NOV 2018, released on November 28, 2018 and available on OLIVARES' website: http://www.olivares.mx)

In the midst of uncertainty concerning the status of COFEPRIS (which may soon be merged with the Central Ministry of Health) as an autonomous agency, the Ministry of Economy has reacted against the guidelines and the importation of products containing cannabis-related substances.

The Ministry of Economy noted that the tariff schedules concerning cannabis and its derivates are still legally forbidden, as COFEPRIS failed to properly request a review process for amendment of the trade regulation prior to the issuance of the guidelines.

Therefore, despite COFEPRIS' issuance of guidelines that allow for the granting of sanitary approvals with respect to commercialization, exploitation, and importation of products containing cannabis-related substances, as long as the modifications in the trade legislation-specifically the tariff schedules-remain unaddressed, the importation of such products will not yet be possible.

However, it might not be long before the necessary modifications are made, as there is a bill presently under discussion in Congress. Both the current and new presidential administrations have expressed their intentions to enact the bill shortly.

The developments in this area will therefore continue to be monitored by OLIVARES partners and associates.

Originally published December 6 2018

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More